^
    5d
    A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=254, Recruiting, Shanghai Henlius Biotech | Active, not recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • EGFR negative
    9d
    Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=3883, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PGR positive • EGFR negative
    |
    Verzenio (abemaciclib) • letrozole • anastrozole
    10d
    TianjinCIH: A Single-center, Phase II Clinical Study of Sacituzumab Govitecan Combined With Toripalimab as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR negative
    |
    Loqtorzi (toripalimab-tpzi) • Trodelvy (sacituzumab govitecan-hziy)
    10d
    Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC. (PubMed, Anticancer Res)
    LM has been attracting attention, possibly due to the long-term survival achieved by EGFR-tyrosine kinase inhibitors. Additional information is required to clarify the risk of LM.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive • EGFR negative
    |
    Tagrisso (osimertinib)
    18d
    Design and Synthesis of Peptide-Tagged Cubosome Nanocarriers for the Targeted Delivery of Paclitaxel in EGFR Overexpressing Breast Cancer. (PubMed, ACS Biomater Sci Eng)
    In vivo, targeted treatment suppressed tumor progression, yielding a mean tumor volume of 330 mm3, compared to 675 mm3 and 770 mm3 in untargeted and control groups, respectively, without observable liver or kidney toxicity. These results highlight the therapeutic potential of peptide-tagged cubosomes for the selective treatment of EGFR-expressing cancers.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR negative
    |
    paclitaxel
    23d
    Breast Conserving Therapy is a Safe Option for Women Under 40 Diagnosed With Breast Cancer. (PubMed, J Surg Res)
    In our cohort with 5-y survival data, BCT is a safe option for women aged 40 y and under who are diagnosed with breast cancer. Despite no survival benefit, young women with breast cancer in our cohort underwent mastectomy more often than lumpectomy. Importantly, most recurrences were distant metastases, suggesting that local therapy choice is less relevant to outcome.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HR positive • EGFR negative
    24d
    A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • EGFR expression • EGFR positive • EGFR negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • SYS6010
    1m
    Clinical study of sPD-1 as a novel diagnostic and therapeutic marker for NSCLC immunotherapy with checkpoint inhibitors: a prospective observational cohort study (ChiCTR2500114895)
    P=N/A, N=142, Not yet recruiting, Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • EGFR negative
    1m
    Expression of B7-H3 in patients with advanced HIV-positive NSCLC and analysis of the efficacy and safety of immune checkpoint inhibitors combined with platinum-based dual drugs in the treatment of advanced HIV-positive NSCLC patients (ChiCTR2500113288)
    P=N/A, N=60, Completed, Guiyang Public Health Clinical Center; Guiyang Public Health Clinical Center
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD4 (CD4 Molecule)
    |
    EGFR negative
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • pemetrexed
    1m
    Sacituzumab tirumotecan plus Immune Checkpoint Inhibitor as Neoadjuvant Therapy for Resectable Stage IIIA–IIIB (N2) Non-small-cell Lung Cancer: A Single-arm, Single-center, Phase II Trial (ChiCTR2600116542)
    P2, N=34, Not yet recruiting, The General Hospital of the Eastern Theater Command of the People's Liberation Army of China; The General Hospital of the Eastern Theater Command of t
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • EGFR negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)
    1m
    Single-arm, open-label, prospective clinical study of the YMN-V138 vaccine for advanced non-small cell lung cancer (ChiCTR2600116270)
    P1, N=10, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CRIPTO (Cripto)
    |
    ALK mutation • EGFR negative
    1m
    Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, University of Malaya
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 fusion • EGFR negative